Rabies Vaccine Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Rabies Vaccine Market Analysis
The rabies vaccine market is expected to register a CAGR of 5.1% over the forecast period.
The COVID-19 pandemic has had a significant impact on the market. The pandemic impacted every aspect of veterinary healthcare, including vaccinations. For instance, as per the study titled, "The urgency of resuming disrupted dog rabies vaccination campaigns: a modeling and cost-effectiveness analysis" published in June 2021, Haiti's 2020 dog vaccination campaign was canceled, and funds were diverted to support the COVID-19 response. It also reported that COVID-19-related postponements to dog vaccination campaigns have been reported in other countries as well. However, the market is gaining traction owing to the resumption of veterinary care services worldwide and growing rabies cases amid the outbreak. For example, in April 2020, the Food and Agriculture Organization published a new policy on livestock production and the supply chain of animal products during the COVID-19 pandemic. According to 2020 data from the Centers for Disease Control and Prevention (CDC), cats, dogs, and several other species were at potential risk of contracting the virus. In addition, in October 2020, a study titled "Coravax rabies virus-based COVID-19 vaccine induces high levels of neutralizing antibodies against SARS-CoV-2" was published in the journal Nature, which studied the rapid development of a new, highly effective, and safe vaccine against COVID-19 using a vector based on the rabies virus, which has proven to be an effective vaccine against several emerging infectious diseases. Therefore, the initial impact of COVID-19 on the market's growth was adverse owing to lockdowns, virus curbing measures, and overall negligence toward the animal sector, however, such developments are expected to boost the market's growth over the coming years.
The increasing number of cases of rabies across the globe is one of the major factors driving the market's growth over the forecast period. Dogs are the leading cause of human rabies mortality and account for up to 99.0% of all human rabies transmissions as of May 2021, according to the World Health Organization (WHO). According to the same source, more than 29.0 million people worldwide seek vaccine bites each year, while 40.0% of individuals infected with suspected rabies are infants under 15 years of age. Rabies occurs on all continents except Antarctica, with over 95.0% of human mortality reported in the Asian and African regions. According to the WHO, rabies kills nearly 59,000 people worldwide each year. The prevention of canine rabies through animal vaccination programs and the elimination of stray dogs is likely to reduce rabies infection, however, canine rabies persists in several countries and exposure to rabies still accounts for more than 90.0% of human rabies infections and 99% of human deaths due to rabies worldwide.
The Association of Southeast Asian Nations (ASEAN) initially adopted a national elimination plan to eradicate human rabies in the region by the end of 2020, although their success has been limited in some areas. Considering the increasing mortality burden due to increasing cases of rabies across the globe, especially in low-income economies, the market is expected to project growth during the forecast period.
However, low immunization rates in dogs and lack of awareness and negligence by the government and public are anticipated to restrain the market growth over the forecast period.
Rabies Vaccine Market Trends
This section covers the major market trends shaping the Rabies Vaccine Market according to our research experts:
The Purified Chick Embryo Cell Rabies Vaccine is Expected to Witness Growth Over the Forecast Period
The purified chick embryo cell vaccine is used to protect people from post-exposure or pre-exposure. The veterinarians who come into contact with animals such as cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus, leading to rising cases of rabies. Purified chick embryo cell rabies vaccines are prepared with the help of primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. This vaccine works by exposing a small dose of the rabies virus to the patient in order to develop immunity to the disease. There are some side effects, such as very high fever, tingling or prickly feelings in fingers or toes, weakness or unusual feelings in arms and legs, problems with balance or eye movement, and trouble while speaking or swallowing. This vaccine can be used for post-exposure or pre-exposure.
The rise in incidences of animal bites and rising government initiatives are expected to propel the growth of the segment studied over the forecast period. For instance, according to the report published by the Center for Disease Control (CDC) in March 2021, around 89.0 million dogs are in the United States and around 4.5 million dog bites occur each year in the United States.
Likewise, in April 2022, the disease prevention and control bureau, Department of Health, Philippines, awarded Metro Drugs Inc., a procurement contract for 2,500,000 doses of purified chick embryo cell rabies vaccine. The total approved budget for this contract is 200,000,000 PHP.
Therefore, such instances are expected to drive the demand for purified chick embryo cell rabies vaccine, thereby propelling the segment's growth over the forecast period.
North America is is Expected to Dominate the Rabies Vaccine Market Over the Forecast Period
The North America region is expected to dominate the overall rabies vaccine market throughout the forecast period. Increasing mortality due to rabies and an increasing number of dog bites and rabies cases in the region are expected to drive the market growth in this region. According to the data published by the Centers for Disease Control and Prevention (CDC) in April 2020, in the United States, nearly 5,000 cases of animal rabies are reported yearly to the CDC, and more than 90.0% of such cases occur in wildlife. In addition, the increasing number of deaths from rabies in North America is also anticipated to propel market growth. For instance, according to 2022 data by the Centers for Disease Control and Prevention, five people died of rabies in the United States in 2021. Therefore, such instances are expected to boost market growth in North America.
Moreover, key product launches, high concentration of market players and manufacturers' presence, acquisitions and partnerships among major players, and government initiatives toward rabies vaccination in the United States are some of the factors driving the market's growth. For instance, in September 2021, the Health Department, New York City Parks, the United States Department of Agriculture, and Cornell University partnered to distribute an oral rabies vaccine to immunize raccoons and protect them from infection with rabies in New York City.
Thus, the rise in the development of effective human rabies vaccines and increasing government initiatives are expected to boost market growth in North America over the forecast period.
Rabies Vaccine Industry Overview
The major market players are focusing on technological advancements and pet care initiatives in collaboration with hospitals and government channels. The competitive landscape includes an analysis of a few international as well as local companies that hold the market shares and are well known, including Zoetis Inc., Merck & Co., Inc., Sanofi SA, Elanco, and Virbac, among others.
Rabies Vaccine Market Leaders
-
Zoetis Inc.
-
Merck & Co., Inc
-
Elanco
-
Sanofi SA
-
Boehringer Ingelheim International GmbH
*Disclaimer: Major Players sorted in no particular order
Rabies Vaccine Market News
- In April 2022, Cadila Pharmaceuticals launched a three-dose recombinant nanoparticle-based G protein rabies vaccine in Ahmedabad. This is a three-dose regimen to be given over a period of one week (on day 0, day three, and day seven) after exposure to the virus. It is the first in a long list of existing rabies vaccines that require five doses.
- In August 2020, Bavarian Nordic A/S announced that it was starting commercial operations in the United States for Rabipur/RabAvert (Rabies Vaccine) and Encepur (Tick-Borne Encephalitis Vaccine) after acquiring them from GlaxoSmithKline plc (GSK).
Rabies Vaccine Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Burden of Mortality due to Rabies
- 4.2.2 Large Population of Stray Dogs in Low and Middle Income Countries
- 4.2.3 Growing Pet Management technological Advancements and Services
-
4.3 Market Restraints
- 4.3.1 Low Immunization Rates in Dogs
- 4.3.2 Lack of Awareness and Negligence by Government and Public
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Product Type
- 5.1.1 Baby Hamster Kidney (BHK)
- 5.1.2 Purified Chick Embryo Cell Rabies Vaccine
- 5.1.3 Vero Cell Rabies Vaccine
- 5.1.4 Other Product Types
-
5.2 By Vaccination Type
- 5.2.1 Pre-Exposure Vaccination (PEV)
- 5.2.2 Post-Exposure Prophylaxis (PEP)
-
5.3 By End-User
- 5.3.1 Animals
- 5.3.2 Humans
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Berna Biotech Ltd
- 6.1.2 GlaxoSmithKline plc
- 6.1.3 Merck & Co Inc
- 6.1.4 Novartis AG
- 6.1.5 Pfizer Inc
- 6.1.6 Sanofi SA
- 6.1.7 Zoetis Inc.
- 6.1.8 Elanco
- 6.1.9 Virbac
- 6.1.10 Boehringer Ingelheim International GmbH
- 6.1.11 Bharat Biotech
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityRabies Vaccine Industry Segmentation
As per the scope of the report, rabies is a viral disease spread by the bite or scratch of an animal. The rabies vaccine is an active immunization agent used to prevent infection caused by the rabies virus. The vaccine works by making antibodies against the rabies virus. The rabies vaccine market is segmented by Product Type (Baby Hamster Kidney (BHK), Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, Other Product Types), Vaccination type (Pre-Exposure Vaccination (PEV), and Post-Exposure Prophylaxis (PEP)), End-User (Animals and Humans), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Product Type | Baby Hamster Kidney (BHK) | |
| Purified Chick Embryo Cell Rabies Vaccine | ||
| Vero Cell Rabies Vaccine | ||
| Other Product Types | ||
| By Vaccination Type | Pre-Exposure Vaccination (PEV) | |
| Post-Exposure Prophylaxis (PEP) | ||
| By End-User | Animals | |
| Humans | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Rabies Vaccine Market Research FAQs
What is the current Global Rabies Vaccine Market size?
The Global Rabies Vaccine Market is projected to register a CAGR of 5.10% during the forecast period (2024-2029)
Who are the key players in Global Rabies Vaccine Market?
Zoetis Inc., Merck & Co., Inc, Elanco, Sanofi SA and Boehringer Ingelheim International GmbH are the major companies operating in the Global Rabies Vaccine Market.
Which is the fastest growing region in Global Rabies Vaccine Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Rabies Vaccine Market?
In 2024, the North America accounts for the largest market share in Global Rabies Vaccine Market.
What years does this Global Rabies Vaccine Market cover?
The report covers the Global Rabies Vaccine Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Rabies Vaccine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Rabies Vaccines Industry Report
Statistics for the 2024 Rabies Vaccines market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Rabies Vaccines analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
